Pluri Inc (PLUR) Stock Price, Quote & News

Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatmen...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 74 710 8600

Website: www.pluri-biotech.com

Address:

MATAM Advanced Technology Park, Building No. 5, Haifa, Israel

PLURI_JUGGERNAUT_ Jun. 7 at 9:43 PM

$PLUR Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing https://markets.businessinsider.com/news/stocks/pluri-advances-toward-u-s-commercial-launch-through-its-subsidiary-cellav-following-completion-of-regenerative-aesthetic-products-listing-1036217213

0 · Reply

DJtraderNY May. 30 at 2:42 AM

$PLUR this thing still trading… knowing the trend id say better to short it always leading to another split

0 · Reply

PLURI_JUGGERNAUT_ May. 20 at 10:22 PM

$PLUR Chairman Alejandro Weinstein has invested a total of 11.5 million in Pluri Biotech through multiple strategic transactions across 2025 and 2026.

1 · Reply

Bumbleclod May. 20 at 9:14 PM

$PLUR scam stock sucking a salary off of shareholders for years......

0 · Reply

PLURI_JUGGERNAUT_ May. 20 at 1:21 PM

$PLUR Just Watched Yaky Yanay's AGP Presentation! (Laser Focused on Revenue Streams) !!! He Reminded Shareholders That Ever After Foods Alone, Currently Has A Valuation of 60 Million! Also, They Are Waiting For FDA/EMA/IMoH Approvals For CellaV Products Any Day Now !!!

0 · Reply

BioRich May. 20 at 7:02 AM

$TEM $URGN $PLUR $IVA $LGND (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam)

0 · Reply

hubal May. 18 at 10:56 AM

$PLUR Pluri Inc. (formerly Pluristem Therapeutics) reported its fiscal third-quarter 2026 earnings on May 14, 2026, posting an EPS of $-\$0.55$, beating the consensus estimate of $-\$0.66$ by $\$0.11$. Quarterly revenue reached $\$167,000$, which missed the estimated $\$660,000$.A more detailed breakdown of their latest financial performance includes:Net Loss: Totaled $\$5.55$ million for the quarter, reflecting a narrowing of the $-\$6.15$ million net loss from the same period in 2025.Fiscal Year-to-Date (Nine Months): The company recorded $\$681,000$ in total sales with a net loss of $-\$17.94$ million.Year-Over-Year Improvement: The quarterly loss per share improved significantly compared to the $-\$0.94$ basic and diluted EPS loss reported in Q3 of the previous year.

0 · Reply

urgetosurge May. 16 at 8:52 PM

$VBIO just like the quantum stocks of late, Ai, bitcoin before, irradiation plays sector should be forthcoming, imo. Some small cap candidates. $RDHL $PLUR $MIR

0 · Reply

PLURI_JUGGERNAUT_ May. 11 at 1:49 PM

$PLUR Finally Got The European Union Patent !!! Pluri Already Has The Rest of the World !!! This Was The Last Piece of The Negotiating Puzzle !!! EP4735027 - GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELL THERAPY https://patentscope.wipo.int/search/en/detail.jsf?docId=EP478576522&_cid=P11-MP18X7-75284-1

0 · Reply

PLURI_JUGGERNAUT_ Apr. 19 at 2:10 PM

$PLUR April Company Presentation Out !!!

0 · Reply

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

2026-03-26T12:46:49.000Z - 2 months ago

Pluri announces additional $2.5M investment from Alejandro Weinstein

2026-02-18T13:26:26.000Z - 3 months ago

Pluri secures global IP position with CNIPA for immune cell expansion

2026-01-22T14:20:47.000Z - 4 months ago

Pluri completes first phase of program with Resbiomed Technologies OOD

2025-12-22T12:10:54.000Z - 6 months ago

Pluri announces expansion of manufacturing agreement with Remedy Cell

Dec 22, 2025, 7:00 AM EST - 6 months ago

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

2025-12-09T13:45:37.000Z - 6 months ago

Pluri appoints Weinstein as Chairman of the Board of Directors

2025-11-11T13:10:38.000Z - 7 months ago

Pluri announces launch of Cellav Health and Aesthetics

2025-11-10T13:15:46.000Z - 7 months ago

Pluri enters series of international collaborations

2025-10-08T13:10:10.000Z - 8 months ago

Pluri subsidiary Coffeesai announces strategic collaboration for manufacturing

2025-09-17T21:30:45.000Z - 9 months ago

Pluri files to sell 3.425M common shares for holders

2025-06-02T11:05:14.000Z - 1 year ago

Pluri re-initiated with a Buy at Alliance Global Partners

May 27, 2025, 7:00 AM EDT - 1 year ago

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

2025-05-15T11:19:26.000Z - 1 year ago

Pluri CEO issues letter to shareholders

2025-04-28T12:22:41.000Z - 1 year ago

Pluri completes strategic acquisition of 71% of equity of Kokomodo for $4.5M

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

2025-04-10T12:35:28.000Z - 1 year ago

Pluri announces USPTO issued patent covering its immune cell expansion tech

2025-03-05T12:23:18.000Z - 1 year ago

Pluri announces exclusive collaboration agreement with Hemafund

Mar 5, 2025, 7:00 AM EST - 1 year ago

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Feb 19, 2025, 9:01 AM EST - 1 year ago

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

2025-02-04T12:16:15.000Z - 1 year ago

Pluri secures additional $3.5M investment from Merchant Adventure Fund

2025-01-23T14:25:16.000Z - 1 year ago

Pluri gets $6.5M investment from Alejandro Weinstein, enters cacao market

2025-01-23T12:25:16.000Z - 1 year ago

Pluri secures $6.5M investment, acquires 71% stake in Kokomodo for $4.5M

Jan 23, 2025, 7:15 AM EST - 1 year ago

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

2024-12-19T13:20:34.000Z - 1 year ago

Pluri congratulates Mesoblast, CEO on FDA approval of MSC-based therapy

$Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Dec 19, 2024, 8:00 AM EST - 1 year ago

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Nov 12, 2024, 1:00 PM EST - 1 year ago

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Nov 11, 2024, 6:00 AM EST - 1 year ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Jul 18, 2024, 2:30 AM EDT - 2 years ago

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Jun 18, 2024, 6:30 AM EDT - 2 years ago

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

Jun 6, 2024, 6:45 AM EDT - 2 years ago

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

May 20, 2024, 7:00 AM EDT - 2 years ago

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

May 2, 2024, 7:00 AM EDT - 2 years ago

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Apr 8, 2024, 7:00 AM EDT - 2 years ago

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Mar 28, 2024, 7:15 AM EDT - 2 years ago

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Pluri Inc. Announces 1-for-8 Reverse Share Split

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Mar 19, 2024, 4:00 AM EDT - 2 years ago

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Mar 6, 2024, 7:00 AM EST - 2 years ago

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Feb 28, 2024, 7:00 AM EST - 2 years ago

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Jan 23, 2024, 2:00 AM EST - 2 years ago

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Jan 8, 2024, 7:00 AM EST - 2 years ago

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Aug 16, 2023, 7:00 AM EDT - 3 years ago

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Jul 13, 2023, 2:00 AM EDT - 3 years ago

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

Jul 11, 2023, 2:00 AM EDT - 3 years ago

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Apr 27, 2023, 7:00 AM EDT - 3 years ago

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Mar 13, 2023, 8:00 AM EDT - 3 years ago

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

Dec 22, 2022, 7:00 AM EST - 3 years ago

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Dec 15, 2022, 4:05 PM EST - 3 years ago

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Nov 10, 2022, 7:00 AM EST - 3 years ago

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Pluri to Present and Participate in Upcoming Conferences

Sep 29, 2022, 7:00 AM EDT - 4 years ago

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Sep 6, 2022, 7:00 AM EDT - 4 years ago

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

Jul 25, 2022, 7:00 AM EDT - 4 years ago

Pluri CEO Issues Shareholder Update

Jul 25, 2022, 1:00 AM EDT - 4 years ago

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Jul 13, 2022, 6:00 AM EDT - 4 years ago

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Mar 28, 2022, 3:00 AM EDT - 4 years ago

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Mar 23, 2022, 7:30 AM EDT - 4 years ago

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Mar 8, 2022, 7:12 AM EST - 4 years ago

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Mar 2, 2022, 7:00 AM EST - 4 years ago

Pluristem CEO Issues Shareholder Update

Feb 24, 2022, 7:00 AM EST - 4 years ago

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Jan 10, 2022, 3:00 AM EST - 4 years ago

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Dec 27, 2021, 7:00 AM EST - 4 years ago

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Nov 15, 2021, 7:10 AM EST - 4 years ago

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Nov 10, 2021, 7:00 AM EST - 4 years ago

Pluristem Receives Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform

Jul 19, 2021, 7:00 AM EDT - 5 years ago

Pluristem Appoints Prof. Varda Shalev MD and Mr.

PLURI_JUGGERNAUT_ Jun. 7 at 9:43 PM

0 · Reply

DJtraderNY May. 30 at 2:42 AM

$PLUR this thing still trading… knowing the trend id say better to short it always leading to another split

0 · Reply

PLURI_JUGGERNAUT_ May. 20 at 10:22 PM

$PLUR Chairman Alejandro Weinstein has invested a total of 11.5 million in Pluri Biotech through multiple strategic transactions across 2025 and 2026.

1 · Reply

Bumbleclod May. 20 at 9:14 PM

$PLUR scam stock sucking a salary off of shareholders for years......

0 · Reply

PLURI_JUGGERNAUT_ May. 20 at 1:21 PM

0 · Reply

BioRich May. 20 at 7:02 AM

$TEM $URGN $PLUR $IVA $LGND (Sorry, using this is a placeholder to see how these track over time from today. Posting late so as to not clog the boards or appear as spam)

0 · Reply

hubal May. 18 at 10:56 AM

0 · Reply

urgetosurge May. 16 at 8:52 PM

$VBIO just like the quantum stocks of late, Ai, bitcoin before, irradiation plays sector should be forthcoming, imo. Some small cap candidates. $RDHL $PLUR $MIR

0 · Reply

PLURI_JUGGERNAUT_ May. 11 at 1:49 PM

0 · Reply

PLURI_JUGGERNAUT_ Apr. 19 at 2:10 PM

$PLUR April Company Presentation Out !!!

0 · Reply

PLURI_JUGGERNAUT_ Apr. 19 at 12:56 PM

$PLUR April 18th Company Presentation Out !!! https://pluri-biotech.com/presentation/

0 · Reply

STACKD0E Apr. 16 at 1:50 PM

$GRDX.X $NN $REKR $PLUR

0 · Reply

SuperGreenToday Apr. 7 at 6:27 PM

$PLUR

0 · Reply

ChelseaFC1 Mar. 13 at 6:23 PM

$PLUR Alllloooooo when will our patience be rewarded?

1 · Reply

PLURI_JUGGERNAUT_ Mar. 2 at 5:38 PM

$PLUR See SEC Filing On February 27, 2026, the Company received a letter from Nasdaq, determining that the Company has regained compliance with Listing Rule 5550(b)(2)

0 · Reply

PLURI_JUGGERNAUT_ Feb. 23 at 7:40 PM

$PLUR The partnership is already underway, with functional validation results expected in the coming months. The partnership will evaluate how cell-based cacao can integrate across multiple categories including: Beverages Dairy Confectionery Industrial-scale testing will focus on functionality, sensory performance, and scalability — critical steps toward commercial validation.

2 · Reply

PLURI_JUGGERNAUT_ Feb. 23 at 11:39 AM

$PLUR Cargill-Kokomodo Collaboration Poised to Scale Cell-Based Cacao https://www.foodingredientsfirst.com/news/cargill-kokomodo-scale-cell-based-cacao.html

0 · Reply

PLURI_JUGGERNAUT_ Feb. 19 at 7:00 PM

$PLUR https://finance.yahoo.com/news/pluri-secures-global-ip-position-130000388.html

0 · Reply

PLURI_JUGGERNAUT_ Feb. 18 at 1:27 PM

$PLUR Pluri Secures Global IP Position with China Patent Grant for Large-Scale Immune Cell Expansion, Complementing Prior U.S. Patent https://pluri-biotech.com/releases/pluri-secures-global-ip-position-with-china-patent-grant-for-large-scale-immune-cell-expansion-complementing-prior-u-s-patent/

0 · Reply

PLURI_JUGGERNAUT_ Feb. 18 at 11:40 AM

$PLUR Israeli firm advances 3D cell tech to tackle disease, aging. https://www.youtube.com/watch?v=rbXTS_fwsG8

0 · Reply

Market Cap	25.46M
Revenue (ttm)	1.34M
Net Income (ttm)	-22.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,685.07%
Debt to Equity Ratio	-2.14

Volume	6,600
Avg Vol	10,696
Day's Range	N/A - N/A
Shares Out	10.79M
Stochastic %K	8%
Beta	0.64
Analysts	Strong Buy
Price Target	$12.00